PREZISTA Drug Patent Profile

Which patents cover Prezista, and what generic alternatives are available?

Prezista is a drug marketed by Janssen Prods and is included in two NDAs. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has forty-eight patent family members in twenty-five countries.

The generic ingredient in PREZISTA is darunavir. There are twenty-five drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the darunavir profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Prezista

A generic version of PREZISTA was approved as darunavir by LUPIN on September 29^th, 2022.

Summary for PREZISTA

International Patents:	48
US Patents:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	82
Clinical Trials:	44
Patent Applications:	7,373
Drug Prices:	Drug price information for PREZISTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PREZISTA
What excipients (inactive ingredients) are in PREZISTA?	PREZISTA excipients list
DailyMed Link:	PREZISTA at DailyMed

See drug prices for PREZISTA

Recent Clinical Trials for PREZISTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Frederick National Laboratory for Cancer Research	Phase 4
Geropharm	N/A
Wits Reproductive Health and HIV Institute	Phase 1

See all PREZISTA clinical trials

Pharmacology for PREZISTA

Drug Class	Protease Inhibitor
Mechanism of Action	Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A Inhibitors HIV Protease Inhibitors

Paragraph IV (Patent) Challenges for PREZISTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PREZISTA	Tablets	darunavir	800 mg	021976	1	2013-05-14
PREZISTA	Tablets	darunavir	600 mg	021976	4	2010-06-23

US Patents and Regulatory Information for PREZISTA

PREZISTA is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Prods	PREZISTA	darunavir	SUSPENSION;ORAL	202895-001	Dec 16, 2011		RX	Yes	Yes	7,700,645*PED				Y
Janssen Prods	PREZISTA	darunavir	TABLET;ORAL	021976-006	Nov 9, 2012	AB	RX	Yes	Yes	7,700,645*PED				Y
Janssen Prods	PREZISTA	darunavir	TABLET;ORAL	021976-001	Jun 23, 2006		DISCN	Yes	No	7,700,645*PED				Y
Janssen Prods	PREZISTA	darunavir	TABLET;ORAL	021976-004	Dec 18, 2008	AB	RX	Yes	No	7,700,645*PED				Y
Janssen Prods	PREZISTA	darunavir	TABLET;ORAL	021976-005	Dec 18, 2008	AB	RX	Yes	No	7,700,645*PED				Y
Janssen Prods	PREZISTA	darunavir	TABLET;ORAL	021976-002	Feb 25, 2008	AB	RX	Yes	No	7,700,645*PED				Y
Janssen Prods	PREZISTA	darunavir	TABLET;ORAL	021976-003	Oct 21, 2008		DISCN	Yes	No	7,700,645*PED				Y

Expired US Patents for PREZISTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Prods	PREZISTA	darunavir	TABLET;ORAL	021976-001	Jun 23, 2006	5,583,131
Janssen Prods	PREZISTA	darunavir	TABLET;ORAL	021976-001	Jun 23, 2006	6,987,102

EU/EMA Drug Approvals for PREZISTA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Darunavir Mylan	darunavir	EMEA/H/C/004068Darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection (see section 4.2).Darunavir Mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4.2):For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated.For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.In deciding to initiate treatment with darunavir co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4.2, 4.4 and 5.1).Darunavir co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection. Darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.2). Darunavir Mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (ART)-naïve (see section 4.2). ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10⁶/L. In deciding to initiate treatment with darunavir in such ART-experienced patients, genotypic testing should guide the use of darunavir (see sections 4.2, 4.3, 4.4 and 5.1).	Authorised	yes	no	no	2017-01-03
Janssen-Cilag International NV	Prezista	darunavir	EMEA/H/C/000707PREZISTA, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight.PREZISTA, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg).In deciding to initiate treatment with PREZISTA co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of PREZISTA.PREZISTA, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV 1) infection.PREZISTA 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:For the treatment of HIV 1 infection in antiretroviral treatment (ART) experienced adult patients, including those that have been highly pre treated.For the treatment of HIV 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.In deciding to initiate treatment with PREZISTA co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of PREZISTA.PREZISTA, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV 1) infection.PREZISTA, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg).PREZISTA 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (ART) naïve.ART experienced with no darunavir resistance associated mutations (DRV RAMs) and who have plasma HIV 1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 106/L. In deciding to initiate treatment with PREZISTA in such ART experienced patients, genotypic testing should guide the use of PREZISTA.	Authorised	no	no	no	2007-02-11
KRKA, d.d., Novo mesto	Darunavir Krka d.d.	darunavir	EMEA/H/C/004891400mg and 800 mg Film-coated TabletsDarunavir Krka d.d., co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.Darunavir Krka d.d., co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection in adult patients (see section 4.2).Darunavir Krka d.d. 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (ART)-naïve (see section 4.2).ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 106/l. In deciding to initiate treatment with darunavir in such ART-experienced patients, genotypic testing should guide the use of darunavir (see sections 4.2, 4.3, 4.4 and 5.1).600mg Film-coated TabletsDarunavir Krka d.d., co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.Darunavir Krka d.d. 600 mg tablets may be used to provide suitable dose regimens (see section 4.2):For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated.For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.In deciding to initiate treatment with darunavir co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir.	Withdrawn	yes	no	no	2018-01-18
KRKA, d.d., Novo mesto	Darunavir Krka	darunavir	EMEA/H/C/004273400 and 800 mgDarunavir Krka, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.Darunavir Krka 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (ART)-naïve (see section 4.2).ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 106/l. In deciding to initiate treatment with darunavir in such ART-experienced patients, genotypic testing should guide the use of darunavir (see sections 4.2, 4.3, 4.4 and 5.1).600 mg Darunavir Krka, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.Darunavir Krka 600 mg tablets may be used to provide suitable dose regimens (see section 4.2):For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated.For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.In deciding to initiate treatment with darunavir co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir.	Authorised	yes	no	no	2018-01-26

International Patents for PREZISTA

See the table below for patents covering PREZISTA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	273964
Australia	3165593
Australia	661086
Canada	2125978	AMELIORATIONS DE COMPOSES CHIMIQUES (IMPROVEMENTS IN CHEMICAL COMPOUNDS)
Czech Republic	286928	Farmaceutický přípravek aktivní proti HIV a způsob jeho přípravy (Pharmaceutical antiviral preparation, active component and process for preparing thereof)
Czech Republic	9401188
Germany	122010000001

Supplementary Protection Certificates for PREZISTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1411918	C300537	Netherlands		PRODUCT NAME: PLERIXAFOR IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VORM; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
1411918	CA 2012 00026	Denmark		PRODUCT NAME: PLERIXAFOR I ALLE FORMER SOM BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/01/09/537/001 20090804
1411918	PA2012011	Lithuania		PRODUCT NAME: PLERIXAFORUM; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
1411918	92033	Luxembourg		92033, EXPIRES: 20240731
1411918	122012000044	Germany		PRODUCT NAME: PLERIXAFOR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER EIN METALLKOMPLEX DAVON; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
1411918	PA2012011,C1411918	Lithuania		PRODUCT NAME: PLERIXAFORUM; REGISTRATION NO/DATE: EU/1/09/537/001 20090731
1411918	C20120014 00064	Estonia		PRODUCT NAME: MOZOBIL - PLERIXAFOR;REG NO/DATE: C(2009)6238 31.07.2009

PREZISTA (darunavir) Market Dynamics and Financial Trajectory: Pricing, Demand Drivers, Exclusivity, and Generic/Biosimilar Risk

Last updated: June 17, 2026

PREZISTA (darunavir) is an established HIV protease inhibitor with revenue driven primarily by sustained antiretroviral therapy (ART) adoption, guideline inclusion, and competitive penetration against other protease inhibitors (PIs) and integrase-based regimens. Market dynamics reflect mature, high-penetration therapy, where price pressure and formulary access dominate near-term growth rather than unit expansion. Financial trajectory is shaped by the shift from PI-centered regimens to integrase inhibitor (INSTI)-centered combinations, and by the availability of multiple generic darunavir products in the US and ex-US markets, which reduces brand pricing power over time.

---

Why is PREZISTA (darunavir) still used in HIV therapy despite INSTI dominance?

PREZISTA remains clinically relevant in specific patient populations where darunavir-based regimens deliver high efficacy and a high genetic barrier to resistance when dosed with a booster (typically ritonavir). In mature HIV markets, that translates into continued demand even as overall ART selection shifts to INSTI combinations.

What clinical positioning supports ongoing PREZISTA demand?

Key demand supports in standard HIV care:

• High virologic suppression rates in treatment-experienced patients when viral resistance profiles support PI activity.
• Established use in patients with prior treatment failure or resistance where INSTI options may be limited by resistance history.
• Convenient dosing options relative to older PIs, depending on formulation and country-specific prescribing norms.
• Guideline continuity in many regions where darunavir-based regimens are still recommended for certain populations.

How does competition from other HIV regimens affect PREZISTA sales?

Competitive pressures typically come from:

• INSTI-based fixed-dose combinations (e.g., dolutegravir-, bictegravir-, or elvitegravir-based regimens) that often offer simpler dosing and strong efficacy.
• Other PIs with strong resistance profiles and payer-friendly access, which can displace darunavir where formulary restrictions apply.
• Combination products that reduce pill burden and can be prioritized by formularies and national treatment programs.

---

How have generics and price erosion changed PREZISTA’s revenue profile?

PREZISTA faces classic brand erosion dynamics for an older small-molecule HIV therapy: once generics gain meaningful market share, brand revenue becomes a function of (1) remaining formulary preference in select plans and (2) lifecycle/contract dynamics rather than new patient starts.

What generic/biosimilar risk exists for darunavir?

Darunavir is a small-molecule antiretroviral; it does not face biosimilar risk, but it does face:

• Generic erosion against branded darunavir tablets.
• Product-and-strength specific substitution based on bioequivalence and formulation parity.
• Competitive switching to fixed-dose combination generics and alternative PI generics.

What does price erosion do to gross-to-net and operating margin?

In branded HIV portfolios:

• Increased net price discounts and rebates commonly accompany generic penetration.
• Gross-to-net typically rises as manufacturers adjust to maintain formulary position.
• Sales decline tends to outpace cost reductions because marketing, contracting, and pharmacovigilance remain necessary at scale.

---

What is the FDA and Orange Book status of PREZISTA?

PREZISTA is an FDA-approved antiretroviral. The practical exclusivity picture for brand revenue is usually determined by a combination of:

• Patent estate over formulations, crystal forms, dosing regimens, and manufacturing processes.
• Patent listings and exclusivity periods in FDA’s Orange Book (for the drug product and related patents).
• Expiration timing that dictates when generic manufacturers can file and when Paragraph IV ANDA challenges can occur.

How does Orange Book status translate into generic launch timing?

Where Orange Book listings exist, they affect:

• The willingness of ANDA filers to launch at risk.
• Settlement likelihood and brand’s ability to maintain market presence through negotiated delays.

What filing and approval mechanics matter for darunavir competition?

For small-molecule HIV drugs:

• ANDA approvals can proceed once relevant patents expire or are found not infringed/invalid under the Hatch-Waxman framework.
• Even after patent expiration, additional time can be consumed by labeling changes, market entry logistics, and payer contracting.

(No Orange Book listing data was provided in the prompt, so no specific Orange Book patents, listing numbers, or expiration dates can be stated here without risking inaccuracy.)

---

When does PREZISTA lose exclusivity, and what launch windows drive revenue step-downs?

Brand revenue step-downs typically occur in phases:

1. Patent litigation or settlement-mediated delay.
2. First generic launches (partial substitution).
3. Broader payer switching and contracting changes.
4. Entrenchment of generics leading to sustained brand decline.

What timing factors drive the magnitude of step-downs?

• Whether generics launch in key strengths and dosage forms at launch date.
• Whether competitors offer therapeutically equivalent alternatives under preferred formulary tiers.
• Whether the brand retains contractual rebates for narrow indications or specific patient cohorts.

How does the HIV regimen shift affect timing beyond exclusivity?

Even without exclusivity changes, HIV prescribing patterns continue to evolve:

• Growth in INSTI-based regimens can reduce the share of new starts on PI-based strategies.
• Treatment simplification trends reduce PI use even when darunavir remains effective.

---

What patent landscape protects PREZISTA, and how strong is the patent estate commercially?

PREZISTA’s commercial protection is typically weaker than it was at launch due to:

• Natural aging of the core molecule patents.
• More frequent generic entry as the product matures.
• The possibility that later-life patents cover incremental formulation or manufacturing changes that may not broadly block substitution.

How do formulation and method-of-use patents affect market share?

Formulation patents can:

• Delay generic approvals for certain strengths or delivery features.
• Create “authorized” or delayed entry patterns where some generic routes remain blocked longer than others.

Method-of-use patents can:

• Complicate labeling-based substitution if claims cover specific dosing regimens, but they rarely prevent therapeutic interchange when labeling allows.

What litigation patterns usually matter for an established HIV drug?

For mature small molecules, patent disputes often resolve through:

• Early settlement agreements under Hatch-Waxman.
• Carve-outs by strength or by formulation.
• Conditional launch dates rather than prolonged brand dominance.

(No specific PREZISTA patent numbers, assignees, or litigation dockets were provided in the prompt, so detailed patent-by-patent strength cannot be listed.)

---

How do key competitors compare with PREZISTA on market adoption and payer preference?

Competition is best analyzed by regimen architecture:

• PIs vs INSTIs: INSTI-heavy first-line and simplification pathways usually gain share over time.
• Same-class PIs: darunavir competes with other boosted PIs, but payer preference often follows guideline placement plus contracting.

What does payer behavior imply for PREZISTA?

• When formularies move to INSTI-based preferred tiers, PI usage shifts toward second-line or resistant cases.
• Payer incentives drive rapid adoption of less expensive generics and fixed-dose combinations when available.

How does “genetic barrier to resistance” translate to commercial outcomes?

Clinical differentiation can preserve usage in resistant cohorts, which helps prevent total brand exit. But it seldom reverses structural pricing pressure once generics are established.

---

What does a typical financial trajectory look like for an HIV PI brand like PREZISTA?

For established HIV brands facing generic entry and regimen mix shift, revenue typically follows:

• High maturity base with steady decline once generics gain traction.
• Volatility tied to payer contracting and bulk purchasing by national programs.
• Incremental declines in the absence of meaningful life-cycle protection.

What are the principal revenue drivers after generic erosion?

• Remaining brand share due to contract performance and patient-level physician preference in resistant cases.
• Continued use in treatment-experienced populations.
• Geographic persistence where generic substitution is slower due to procurement practices or tender cycles.

What are the principal cost-side constraints?

• Continued pharmacovigilance obligations and ongoing distribution.
• Less flexibility in cost structure because brand activity persists even as volume declines.

(No specific PREZISTA financial statements, quarterly revenue figures, or company guidance were supplied in the prompt, so exact numbers cannot be produced without risking fabrication.)

---

How do geography and tender cycles affect PREZISTA’s financial path outside the US?

International markets can differ materially:

• National formularies and tender systems can create slower diffusion of generics.
• Some regions maintain branded access longer due to procurement policies, negotiated pricing, or limited generic supply at launch.
• Other regions switch quickly once ANDA equivalents are available.

What commercial factors typically govern ex-US timing?

• Competitive intensity among local generic manufacturers.
• Regulatory timelines for generic approvals and product labeling.
• Government tender structures and preferred supplier lists.

---

What generic entry risks exist for PREZISTA products (by formulation and strength)?

The risk is not uniform. For a given active, substitution tends to follow:

• Strength-specific patent and listing outcomes.
• Bioequivalence and formulation-specific restrictions.
• Supply readiness and distribution coverage.

What creates “pockets” of remaining brand demand?

• Strengths or dosing regimens with more complex patent or regulatory constraints.
• Patient segments requiring specific formulation characteristics.
• Limited payer willingness to switch immediately when patient stability is valued.

---

What would a successful licensing or settlement strategy have protected for PREZISTA?

If brand pursued lifecycle protection or negotiated entry management, the commercial objective would be:

• Delay market share transfer to generics at the highest-revenue strengths.
• Preserve contracting leverage during early generic launches.
• Reduce at-risk launch incentives by shaping litigation timelines.

What settlement structures are common in this category?

• Timed generic launch dates.
• Strength-specific restrictions.
• Carve-outs for noninfringing versions or alternative routes.
• Payment-based settlements, where legally permitted and documented.

(No specific PREZISTA settlement agreement details were provided in the prompt, so no deal terms can be asserted.)

---

What does the current competitive landscape imply for near-term PREZISTA revenue?

Near-term revenue tends to be constrained by:

• Continued PI share dilution as INSTI-based first-line regimens dominate.
• Ongoing generic price pressure and payer preference for low-cost equivalents.
• Contracting that accelerates brand decline when generics are readily interchangeable.

Base-case market behavior

• Stable but declining brand revenue, with usage concentrated in treatment-experienced or resistant cohorts.
• Incremental declines driven by switching to preferred INSTI-based combinations.
• Limited upside unless new life-cycle advantages (new formulations, new indications, or exclusive supply arrangements) materially change access.

---

Key Takeaways

• PREZISTA demand persists mainly due to clinical utility in treatment-experienced or resistant HIV populations with a strong dosing/efficacy profile when boosted.
• Financial trajectory is typically shaped less by new patient growth and more by generic-driven price erosion, payer contracting, and regimen-mix shift toward INSTI-centered therapy.
• Exclusivity and patent estate effects translate into “step-down” events tied to generic launches by strength and formulation, followed by sustained brand decline.
• Geographic tender and formulary mechanics can slow or accelerate erosion outside the US, creating regional revenue pockets.
• Without lifecycle advantages that block substitution at key strengths, near-term upside is limited as generics and INSTI competition dominate.

---

FAQs

1) Does PREZISTA revenue depend more on new starts or on treatment-experienced patients?

Mostly treatment-experienced and resistant cohorts, where boosted PI selection remains clinically justified.

2) Are there major biosimilar risks to PREZISTA?

No. Darunavir is a small molecule, so the competitive threat is generic entry, not biosimilars.

3) Can a patent on a specific PREZISTA formulation delay generic substitution?

Yes, if the formulation, crystal form, or manufacturing method is covered by enforceable listings and affects approval pathways for specific strengths.

4) How does INSTI adoption change the long-term outlook for HIV PIs like darunavir?

It reduces first-line PI usage over time, pushing PI use toward later lines and resistance-driven prescribing, which limits brand growth.

5) What market factor most strongly accelerates brand erosion after generic approval?

Payer contracting and formulary switching, which often drive faster share transfer than clinical preference alone.

---

References (APA)

(No citable sources were provided in the prompt for PREZISTA Orange Book status, patent numbers, litigation, or financial figures, so no inline citations or reference entries can be generated without fabricating data.)